Skip Nav Destination
Issues
1 September 2016
-
Cover Image
Cover Image
CEA TCB (magenta), a novel T-cell bispecific antibody, specifically binds LS174T tumor cells (red) subcutaneously cografted with huPMBCs (green T cells) into the skin of mice. Tumor-cell targeting by CEA TCB is demonstrated by intravital, 2-photon microscopic imaging, 24 hours after intravenous injection of fluorescently (A647) labeled CEA TCB. For details, see the article by Lehmann and colleagues on page 4417 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Statistics in CCR
Molecular Pathways
Review
Perspective
Cancer Therapy: Clinical
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
Arta M. Monjazeb; Michael S. Kent; Steven K. Grossenbacher; Christine Mall; Anthony E. Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L. Shiao; Abhinav Reddy; Julian R. Perks; William T.N. Culp; Ellen E. Sparger; Robert J. Canter; Gail D. Sckisel; William J. Murphy
A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
Leo Rasche; Emmanuelle Menoret; Valentina Dubljevic; Eline Menu; Karin Vanderkerken; Constantin Lapa; Torsten Steinbrunn; Manik Chatterjee; Stefan Knop; Johannes Düll; Deanne L. Greenwood; Frank Hensel; Andreas Rosenwald; Hermann Einsele; Stephanie Brändlein
Personalized Medicine and Imaging
A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Florence Magrangeas; Rowan Kuiper; Hervé Avet-Loiseau; Wilfried Gouraud; Catherine Guérin-Charbonnel; Ludovic Ferrer; Alexandre Aussem; Haytham Elghazel; Jérôme Suhard; Henri Der Sakissian; Michel Attal; Nikhil C. Munshi; Pieter Sonneveld; Charles Dumontet; Philippe Moreau; Mark van Duin; Loïc Campion; Stéphane Minvielle
Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Manuela Krumbholz; Julia Hellberg; Benedikt Steif; Tobias Bäuerle; Clarissa Gillmann; Torsten Fritscher; Abbas Agaimy; Benjamin Frey; Joerg Juengert; Eva Wardelmann; Wolfgang Hartmann; Heribert Juergens; Uta Dirksen; Markus Metzler
Cancer Therapy: Preclinical
Author Choice
Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Rania Bassiouni; Kathleen N. Nemec; Ashley Iketani; Orielyz Flores; Anne Showalter; Amr S. Khaled; Priya Vishnubhotla; Robert W. Sprung, Jr; Charalambos Kaittanis; Jesus M. Perez; Annette R. Khaled
Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Nicola J. Mason; Josephine S. Gnanandarajah; Julie B. Engiles; Falon Gray; Danielle Laughlin; Anita Gaurnier-Hausser; Anu Wallecha; Margie Huebner; Yvonne Paterson
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression
Nicholas F. Evageliou; Michelle Haber; Annette Vu; Theodore W. Laetsch; Jayne Murray; Laura D. Gamble; Ngan Ching Cheng; Kangning Liu; Megan Reese; Kelly A. Corrigan; David S. Ziegler; Hannah Webber; Candice S. Hayes; Bruce Pawel; Glenn M. Marshall; Huaqing Zhao; Susan K. Gilmour; Murray D. Norris; Michael D. Hogarty
Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Hiroki Tanaka; Hiroshi Fujiwara; Fumihiro Ochi; Kazushi Tanimoto; Nicholas Casey; Sachiko Okamoto; Junichi Mineno; Kiyotaka Kuzushima; Hiroshi Shiku; Takashi Sugiyama; A. John Barrett; Masaki Yasukawa
Author Choice
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Steffi Lehmann; Ramanil Perera; Hans-Peter Grimm; Johannes Sam; Sara Colombetti; Tanja Fauti; Linda Fahrni; Teilo Schaller; Anne Freimoser-Grundschober; Jörg Zielonka; Szymon Stoma; Markus Rudin; Christian Klein; Pablo Umana; Christian Gerdes; Marina Bacac
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J. Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J. Wang; Hai Lin; Jeffrey W. Taub; Yubin Ge
Biology of Human Tumors
Author Choice
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Amos C. Hung; Steven Lo; Ming-Feng Hou; Yi-Chen Lee; Chun-Hao Tsai; Yuan-Yin Chen; Wangta Liu; Yu-Han Su; Yi-Hsuan Lo; Chie-Hong Wang; Shiou-Chen Wu; Ya-Ching Hsieh; Stephen Chu-Sung Hu; Ming-Hong Tai; Yun-Ming Wang; Shyng-Shiou F. Yuan
Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Xin Chen; Qiuhui Li; Xin Liu; Can Liu; Ruifang Liu; Kiera Rycaj; Dingxiao Zhang; Bigang Liu; Collene Jeter; Tammy Calhoun-Davis; Kevin Lin; Yue Lu; Hsueh-Ping Chao; Jianjun Shen; Dean G. Tang
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds